Objective: Temsirolimus (CCI-779) is a novel inhibitor of the mammalian target of rapamycin. This Phase 1 study was aimed at investigating the maximum-tolerated dose, toxicity, pharmacokinetics and antitumor activity in Japanese patients with advanced solid tumors. Methods: Temsirolimus was given as a 30 min intravenous infusion once a week. Patients with solid tumors not amenable to standard forms of treatment were eligible. Dose escalation of temsirolimus was planned from 15, 45, 80 to 165 mg/m 2 . The pharmacokinetics of temsirolimus and sirolimus in whole blood were examined for cycles 1, 2, 4 and 5 of treatment.
INTRODUCTION
Temsirolimus (CCI-779), a novel inhibitor of mammalian target of rapamycin (mTOR), is an ester analogue of the immunosuppressive agent sirolimus (rapamycin, trade name: Rapamune w , sale: Pfizer Inc.), which was approved for the prophylaxis of organ rejection in patients receiving renal transplants in the USA. Temsirolimus inhibits several key signal transduction pathways regulating G1 phase of the cell cycle by inhibiting the activity of mTOR, a cell cycle regulatory kinase, and ultimately blocks progression from G1 to S phase of the cell cycle (1) . Temsirolimus is also reported to show an inhibitory effect on the growth of various tumor cells, especially on the tumor cells with mutation or deletion of PTEN ( phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor gene (2 -10) .
On the basis of the inhibitory effect of temsirolimus on the growth of tumor cells in preclinical studies, clinical studies of temsirolimus have been conducted in patients with a variety of malignant tumors, including advanced renal cell carcinoma (13 -20,22,23) . In the USA, temsirolimus has been approved for the treatment of advanced renal cell carcinoma. In Europe, temsirolimus has been approved for the first-line treatment of patients with advanced renal cell carcinoma who have at least three of six poor prognostic factors (Trade name: Torisel w , INN: temsirolimus, sale: Pfizer Inc. (21, 24) ). The recommended dose of temsirolimus is 25 mg/ body infused intravenously over a 30 -60 min period once a week.
On the basis of the above results, a Phase 1 study was also conducted in Japan to investigate the safety, tolerability, pharmacokinetics and antitumor activity of temsirolimus in patients with advanced solid tumors. Two different temsirolimus schedules were used in US, European and international studies (daily for 5 days every second week and once a week) and showed that temsirolimus was well tolerated and had antitumor activity (14, 15, 22, 23) . The weekly administration was chosen for the conduct of this clinical study in Japan because this is the schedule that has been approved in the USA and Europe and it is a more convenient schedule for patients than daily for 5 days every second week.
PATIENTS AND METHODS

STUDY DESIGN
This was an open-label, single-center, Phase 1 study. The primary objective was to investigate the safety and tolerability of temsirolimus administered by a 30 min intravenous infusion once a week. The secondary objective was to collect preliminary data of the pharmacokinetics and antitumor activity of temsirolimus.
The study protocol was approved by the institutional review board of the National Cancer Center, and the study was conducted from October 2002 to March 2005 in accordance with Good Clinical Practice.
PATIENTS
Patients were enrolled in the study only if they met the following entry criteria: Inclusion criteria were: (i) histologically and cytologically confirmed diagnosis of advanced solid tumors; (ii) refractory to standard therapy or no appropriate therapy; (iii) measurable lesion; (iv) at least 4 weeks since any prior chemotherapy, hormonal therapy, radiation therapy and/or surgery, and any other investigational agent use (at least 6 weeks since nitrosourea and mitomycin C); (v) available to be hospitalized from the day before the first administration through the fourth week; (vi) age 20 and ,75 years at the time of consent; (vii) neutrophil count 1500/mm 3 , platelet count 100 000/mm 3 , hemoglobin 8.5 g/dl; (viii) adequate renal function: serum creatinine ,1.5 mg/dl, creatinine clearance (24 h method) 50 ml/min; (ix) adequate hepatic function: total bilirubin ,2 mg/dl, glutamic oxaloacetic transaminase (aspartate aminotransferase, AST) and glutamic pyruvic transaminase (alanine aminotransferase, ALT) ,3 times the institutional upper limit of the normal range; (x) serum cholesterol 350 mg/dl, triglyceride 500 mg/dl; (xi) performance status 0 -2; (xii) estimated life expectancy of at least 3 months and (xiii) written informed consent for the study. Exclusion criteria were: (i) concomitant use of CYP3A4 inhibitors or inducers, such as anticonvulsants and rifampicin, where the treatment could not be discontinued or switched to a different medication; (ii) symptomatic brain metastasis; (iii) positive HIV antibody, HBs antigen or HCV antibody; (iv) infection requiring systemic medication; (v) complications that were difficult to control by medication or other therapies; (vi) use of immunosuppressive agents within 3 weeks prior to enrollment; (vii) regular use of steroids; (viii) concurrent angina, myocardial infarction within 6 months prior to starting study or heart disease that was difficult to control with medication or other therapies; (ix) history of hypersensitivity to diphenhydramine or its structurally related antihistamine drugs; (x) history of hypersensitivity to polysorbate 80 or polyethylene glycol contained in the diluent of the investigational drug, (xi) women who were pregnant or lactating, or not willing to use acceptable contraception during the study and for at least 3 months following the last study drug administration and (xii) inappropriate patients for the study for any other reason such as screening test results by the investigator.
DOSAGE AND ADMINISTRATION
Temsirolimus was supplied by Wyeth K.K. (Tokyo, Japan) in 5 ml vials for intravenous injection; each contained 25 mg/ml of temsirolimus, co-packaged with a specific diluent.
Diphenhydramine, an antihistamine drug, was intravenously infused at a dose of 30 mg over 30 min 1 h before the temsirolimus administration to prevent hypersensitivity reactions. Approximately 30 min after the diphenhydramine infusion, temsirolimus was administered by a 30 min intravenous infusion.
The doses of temsirolimus were 15, 45, 80 or 165 mg/m 2 . The 15, 45 and 165 mg/m 2 doses correspond to flat doses of 25, 75 and 250 mg. The latter were used once a week in a Phase 2 clinical study in kidney cancer patients and tolerability and efficacy were observed at all doses (14) . Thus, these doses were used in this study of Japanese patients. In addition, 80 mg/m 2 was used as an intermediate dose between 45 and 165 mg/m 2 so that there would not be a 3.7-fold increase in dose in the escalation. Temsirolimus was administered once a week as used previously (14, 15, 22) and at least three administrations were planned. The fourth or subsequent administrations of temsirolimus were allowed to continue until tumor progression or unacceptable toxicity occurred.
DOSE ESCALATION METHOD
On the basis of the Guidelines for Clinical Evaluation of Anticancer Drugs (11), three patients were administered temsirolimus in each dose group. Additional patients were treated at that dose level or dose escalation was performed according to the number of patients with unacceptable toxicity.
DEFINITION OF DOSE-LIMITING TOXICITY
Tolerability of temsirolimus was assessed on the basis of the safety evaluation of the initial three-weekly administrations. When the following events related to temsirolimus occurred before the fourth administration, the event was defined as unacceptable toxicity: (i) Grade 3 or 4 non-hematologic toxicity (exclusion: nausea or vomiting without the use of appropriate antiemetic drugs, and serum triglycerides ,1500 mg/dl recovering to Grade 2 by the next week), (ii) Grade 4 thrombocytopenia, (iii) Grade 4 neutropenia lasting 5 days or more, (iv) Grade 4 febrile neutropenia or (v) delay of administration for 2 weeks or more due to prolonged toxicity.
The severity of toxicities was assessed according to National Cancer Institute Common Toxicity Criteria (NCI-CTC Version 2.0, 30 April 1999).
EFFICACY EVALUATION
On the basis of the guidelines of Response Evaluation Criteria in Solid Tumors (RECIST) (12), best overall response was assessed.
PHARMACOKINETICS
Blood samples were collected at 0, 0.25, 0.5, 1, 2, 4, 6, 24, 72, 96 and 168 h ( just before the time of second administration) after the first administration of temsirolimus and at the time of fifth administration (168 h after the fourth administration). Blood concentrations of temsirolimus and sirolimus, a major active metabolite, were measured by Taylor Technology Inc. (NJ, USA) using a validated liquid chromatography/tandem mass spectrometry method. The limit of detection was 0.25 ng/ml for each compound. The pharmacokinetic parameters of temsirolimus and sirolimus in whole blood, including maximum concentration (C max ), time to maximum concentration (t max ), terminal half-life (t 1/2 ), area under the concentration-versus-time curve (AUC), apparent clearance (corrected for unknown fraction of drug metabolized; CL/f m ) and apparent volume of distribution at steady state (Vd ss /f m ), were calculated using a non-compartmental analysis technique.
RESULTS
PATIENTS' CHARACTERISTICS
Ten patients with solid tumors were enrolled in this study ( Table 1 ). The median age was 60.5 years with a range of 41 -69 years. All patients had at least one prior chemotherapy and seven patients also had surgery for primary tumors.
The primary cancer of five patients was renal cell carcinoma. Three patients had lung cancer and two had colon/colorectal cancer. With regard to prior chemotherapy, five patients had received four or more regimens.
DOSE ESCALATION AND UNACCEPTABLE TOXICITY
The starting dose of 15 mg/m 2 was administered to three patients. One subject discontinued temsirolimus treatment after the first administration because of Grade 4 gastrointestinal perforation. The Efficacy and Safety Evaluation Committee determined that this adverse event was not an unacceptable toxicity, and the patient was excluded from tolerability evaluation and another patient was enrolled. The other three patients in the 15 mg/m 2 dose group did not develop unacceptable toxicity and the escalated dose of 2 (29%). Temsirolimus-related adverse events of any grade that occurred in any cycle in at least six patients were hypophosphatemia (90.0%), diarrhea (80.0%), hyperglycemia (80.0%), stomatitis (70.0%), pyrexia (70.0%), elevated AST (70.0%), rash (70.0%), reduced neutrophil count (60.0%), elevated ALT (60.0%), anorexia (60.0%), hypertriglyceridemia (60.0%) and somnolence (60.0%) ( Table 2 ).
The adverse events of Grade 3 or higher that were related to temsirolimus treatment are as follows. In the period from the first to the third dose of temsirolimus, two patients had diarrhea and one patient each had a perforated digestive tract, stomatitis, malaise, hyperglycemia, hypokalemia or hypophosphatemia (Table 2 ). In the fourth and subsequent administrations, two patients had supraventricular arrhythmia and one each had pulmonary infection and hypercholesterolemia. The perforated digestive tract, malaise, hypercholesterolemia and supraventricular arrhythmia (one patient) occurred in the 15 mg/m 2 group and the diarrhea, stomatitis, hyperglycemia, hypophosphatemia, hypokalemia, pulmonary infection and supraventricular arrhythmia (one patient) occurred in the 45 mg/m 2 group. These adverse events resolved when temsirolimus treatment was stopped and the patients were treated appropriately.
For Grade 2 or lower adverse events of hemoglobin decreased, hematocrit decreased, alkaline phosphatase increased, epistaxis and onychia, the frequency of occurrence increased with the number of administrations of temsirolimus. However, for the adverse events of Grade 3 or higher, the frequency of occurrence did not increase with the number of administrations.
The reasons for discontinuing temsirolimus treatment in this trial were adverse events (four patients), progressive disease (PD; five patients) and other (one patient). Diarrhea, perforated digestive tract, stomatitis and supraventricular arrhythmia were the adverse events that led to discontinuation. No patients died in this trial.
ANTITUMOR ACTIVITY
All 10 patients who received temsirolimus were eligible for this study and were included in efficacy evaluation. Eight patients had stable disease (SD) and two patients had PD as their best overall responses. Of those with SD, 71% (5/7) received temsirolimus 15 mg/m 2 and 100% (3/3) received temsirolimus 45 mg/m 2 . The median length of SD was 35 days (range 20þ to 371 days, Table 3 ). Three patients with renal cell carcinoma who received temsirolimus 15 mg/m 2 had a long period of SD (113 -371 days).
PHARMACOKINETICS
Whole blood samples were collected from seven patients in the 15 mg/m 2 dose group and three patients in the 45 mg/m 2 dose group for measurement of concentrations of temsirolimus and sirolimus. After the intravenous infusion of temsirolimus was completed, concentrations of temsirolimus in whole blood decreased more rapidly than those of sirolimus. After a single dose of temsirolimus, mean C max for temsirolimus increased in a dose-dependent manner but mean AUC did not ( 2 , respectively. After a single dose of temsirolimus, sirolimus mean C max and AUC were increased with increasing dose; however, they did not increase in a dose-proportional manner (Table 4) . A similar dose-proportional increase in sirolimus was observed in the previous study (22) . Mean Vd ss /f m and CL/f m also appeared to increase with increasing dose. Mean terminal half-life for sirolimus was 67.04 and 59.15 h for 15 and 45 mg/m 2 , respectively, and, therefore, was longer than t 1/2 for temsirolimus. After a single dose of temsirolimus, mean AUC sum also exhibited a dose-dependent increase. Mean AUC ratio was 2.94 after the 15 mg/m 2 dose and 4.79 after the 45 mg/m 2 dose. Inter-subject variability was generally modest after single and multiple doses of temsirolimus.
DISCUSSION
This Phase 1 trial in Japanese patients with advanced solid tumors showed that 15 mg/m 2 temsirolimus infused intravenously once a week was well tolerated. The result of evaluation by dose groups demonstrated that none of the patients in 15 mg/m 2 dose group experienced unacceptable toxicity, whereas two of three patients experienced Grade 3 stomatitis and diarrhea in 45 mg/m 2 dose group. For single doses of 15 or 45 mg/m 2 , the exposure of temsirolimus and its major active metabolite sirolimus in whole blood increased in a dose-dependent but subproportional manner. Inter-subject variability between single (the first) and multiple (the fourth) dosing periods was low. The pharmacokinetic parameters for 
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Phase 1 study of temsirolimus in solid tumors temsirolimus and sirolimus that were measured in this study were very similar to those measured in the Phase 1 study of patients with solid tumors treated with intravenous temsirolimus on a weekly schedule (22) and in the Phase 2 study of patients with renal cell carcinoma treated with temsirolimus on a weekly schedule (14) . The common temsirolimus-related adverse events were hypophosphatemia, diarrhea, hyperglycemia, stomatitis, pyrexia, elevated AST, rash, reduced neutrophil count, elevated ALT, anorexia, hypertriglyceridemia and somnolence. These adverse events also have been reported in other studies of patients treated with temsirolimus (14, 15, 22, 23) . Because only 10 Japanese patients were treated in this study, we cannot accurately determine whether the incidence of these adverse events in this population is similar to the incidence in populations in other studies.
In the Phase 3, international, interferon-a-controlled study of temsirolimus conducted in patients with advanced renal cell carcinoma, the patients administered temsirolimus alone at the dose of 25 mg/body (15 mg/m 2 ) demonstrated a significant improvement in overall survival and progression-free survival when compared with the patients administered interferon-a alone (15) . There was no significant difference in the objective response rate ( percentage of patients with complete and partial responses) for patients treated with temsirolimus or interferon-a but patients treated with Renal cell carcinoma SD 27þ
Non-small cell carcinoma SD 42þ SD, stable disease; PD, progressive disease. temsirolimus had a significantly higher clinical benefit rate (percentage of patients with complete and partial responses and SD for at least 24 weeks) than did patients treated with interferon-a. Thus, long-term SD was an important component of the temsirolimus response in patients with advanced renal cell carcinoma. For patients treated with temsirolimus, the objective response rate was 9% and the clinical benefit rate was 32%. In this Phase 1 study, three (3) patients with renal cell carcinoma had long-term SD lasting 113 -371 days. The fact that 3 of 10 Japanese patients had long-term SD and none had partial or complete responses agrees with the results obtained in the Phase 3 study and suggests that the antitumor activity of temsirolimus in Japanese cancer patients is similar to that in renal cell carcinoma patients of the international population. From the above results, tolerability at 15 mg/m 2 was confirmed, and the recommended dose for Japanese patients with advanced solid tumors was determined to be temsirolimus 15 mg/m 2 as an intravenous infusion once a week. Further clinical studies will be required to investigate the safety and efficacy of temsirolimus in detail.
